医药创新为何需要“价格凭证”(微观)
Ren Min Ri Bao·2025-12-11 21:57

Core Insights - The launch of China's drug price registration system marks a significant step towards providing a transparent and authoritative pricing platform for pharmaceutical companies, facilitating their global pricing strategies and supporting innovation in the industry [1][2] Group 1: Drug Price Registration System - The new drug price registration system is independent of provincial procurement platforms and aims to offer a standardized market price inquiry service for companies [1] - Nine leading domestic and international pharmaceutical companies have completed the first batch of drug price registrations [1] Group 2: International Market Expansion - By the third quarter of 2025, Chinese pharmaceutical companies completed 103 overseas transactions, with a total transaction value exceeding $92 billion [1] - The lack of reliable pricing references due to low domestic insurance payment prices poses challenges for Chinese companies in international markets [1] Group 3: Policy Support and Innovation - The Chinese government emphasizes the importance of policy support for innovation in pharmaceuticals, as highlighted in the "14th Five-Year Plan" [3] - Local governments are implementing various supportive measures, such as the establishment of clinical trial quality management institutions and reforms in drug licensing, to enhance the innovation ecosystem [2][3] Group 4: R&D Investment and Challenges - The pharmaceutical industry faces high risks, long cycles, and significant investments in new drug development, with an average development time of 10 years and costs around $1 billion [2] - Despite advancements, most domestic biopharmaceutical research remains in the realm of follow-up or imitation innovation, limiting the industry's overall growth [3] Group 5: Health and Economic Impact - The development of innovative drugs is crucial for public health and the competitiveness of the national biopharmaceutical industry [2] - Enhanced policy support and innovation in the biopharmaceutical sector are expected to lead to the production of more effective medications, ultimately benefiting public health [3]